Incretin pathway plays an important role in the development of diabetes medications.
Interventions in DPP-4 and GLP-1 receptor have shown remarkable efficacy in experimental …

Background and Purpose Glucagon‐like peptide‐1 (GLP‐1) and glucagon (GCG) receptor
dual agonist have promising therapeutic effects in the treatment of obesity and diabetes …

GLP-1 receptor (GLP-1R) and neuropeptide Y2 receptor (Y2R) dual agonists have shown
great potential to treat obesity and type 2 diabetes (T2DM). We developed a multitarget …

The combination of incretin-based therapies and PYY analogue has shown great potential
for the treatment of type 2 diabetes (T2DM) and obesity. In this study we developed the first …

The combined use of gastrointestinal hormones for treating metabolic diseases is gaining
increasing attention. It was documented previously that co-administration of a …

Dual activation of the glucagon receptor (GCGR) and glucagon-like peptide 1 receptor (GLP-
1R) has the potential to lead to an effective therapy for the treatment of diabetes and obesity …

Diabetes is characterized by pancreas dysfunction and is commonly associated with obesity.
Hypoglycemic agents capable of improving β-cell function and reducing body weight …

A pair of glucagon-like peptide-1 (GLP-1) analogs (1 and 2) were synthesized by hybridizing
the key sequences of GLP-1, exendin-4, lixisenatide, and xenGLP-1B (Xenopus GLP-1 …

The combined use of gastrointestinal hormones for treating metabolic diseases is gaining
increasing attention. The potential of developing novel dual agonists targeting both …

GLP-1 analogs suffer from the main disadvantage of a short in vivo half-life. Lithocholic acid
(LCA), one of the four main bile acids in the human body, possesses a high albumin binding …